Optic Neuropathy, Ischemic

PORT WASHINGTON, N.Y., April 15, 2025 /PRNewswire/ -- Parker Waichman LLP, a nationally recognized law firm dedicated to representing victims of defective drugs and devices, recently filed a lawsuit against Novo Nordisk on behalf of a New Jersey based Plaintiff diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION). NAION, a debilitating eye condition, is linked to the active ingredient, semaglutide, in Ozempic and Wegovy. The case is now pending in the Superior Court of New Jersey, Middlesex County. Parker Waichman LLP is urging individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact the firm for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk. Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness. Parker Waichman LLP Fighting for Victims Nationwide "NAION is a devastating, permanent eye injury. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable," said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Parker Waichman LLP Phone: 1-800-YOUR-LAWYER (1-800-968-7529) Website: SOURCE Parker Waichman LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

National Law Firm Filed One of the First Eye Injury Cases against Novo Nordisk in the Superior Court of New Jersey, Middlesex County PORT WASHINGTON, N.Y., April 14, 2025 /PRNewswire/ -- Parker Waichman LLP, a nationally recognized law firm dedicated to representing victims of defective drugs and devices, recently filed a lawsuit against Novo Nordisk on behalf of a New Jersey based Plaintiff diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION). NAION, a debilitating eye condition, is linked to the active ingredient, semaglutide, in Ozempic and Wegovy. The case is pending in the Superior Court of New Jersey, Middlesex County. The firm is urging individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact Parker Waichman LLP for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk. Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness. Parker Waichman LLP Fighting for Victims Nationwide "NAION is a devastating, permanent eye injury. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable. " said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Parker Waichman LLP Phone: 1-800-YOUR-LAWYER (1-800-968-7529) Website: SOURCE Parker Waichman LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TUESDAY, April 8, 2025 -- For patients with diabetes , semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a study published online March 27 in JAMA Ophthalmology . Alan Y. Hsu, M.D., from the China Medical University Hospital in Taichung City, Taiwan, and colleagues conducted a cohort study to examine the association between semaglutide use and risk for NAION among patients with diabetes. The semaglutide cohort was compared to a control group of randomly selected patients with diabetes who were prescribed non-glucagon-like peptide 1 (non-GLP-1) receptor agonist (RA) medications (174,584 patients in each group). The researchers found that patients with diabetes taking semaglutide had an absence of NAION risk at the one-month, three-month, six-month, and one-year time points after the index date. However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively). Patients with diabetes and concomitant hypertension who were taking semaglutide had an increased risk for NAION (hazard ratio, 2.42). Patients with diabetes who had a history of Ozempic use or stand-alone Ozempic prescription history also had increased NAION risk. "Among patients with diabetes, an elevated risk of NAION was associated with semaglutide use compared with non-GLP-1 RA use," the authors write. "However, the study's retrospective design can only infer associations rather than establish causality."